Karpova, D., Rettig, M.P., Ritchey, J., (…), Link, D.C., *DiPersio, J.F., The Journal of clinical investigation, 130, 2019.
Immune escape of AML cells after transplantation (Links to an external site)
Marín-Hernández, D., Iñiguez, L.P., Nixon, D.F., (…), *DiPersio, J.F., Ley, T.J., New England Journal of Medicine, 380(13), pp. 1289-1290, 2019.
DiPersio leads 1st US clinical trial with ApoGraf to prevent GvHD (Links to an external site)
Dr. John DiPersio (Department of Medicine, Chief, Division of Oncology) will lead the first US Phase I/II clinical trial for ApoGraf, a stem cell selection technology developed by Cellect Biotechnology. ApoGraf is designed to prevent acute Graft vs. Host Disease following bone marrow transplant.
New paper from the DiPersio Lab (Links to an external site)
Alahmari, B., Cooper, M., Ziga, E., (…), DiPersio, J.F., Choi, J. Selective targeting of histone modification fails to prevent graft versus host disease after hematopoietic cell transplantation. PLoS One, 13, p.e0207609, 2018.